Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer

Ottavio De Cobelli, Carlo Buonerba, Daniela Terracciano, Danilo Bottero, Giuseppe Lucarelli, Pierluigi Bove, Vincenzo Altieri, Ioman Coman, Sisto Perdonà, Gaetano Facchini, Massimiliano Berretta, Giuseppe Di Lorenzo, Paolo Grieco, Ettore Novellino, Renato Franco, Michele Caraglia, Claudia Manini, Vincenzo Mirone, Sabino De Placido, Guru SonpavdeMatteo Ferro

Research output: Contribution to journalArticlepeer-review


Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients. Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry. Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55-68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23-100.48). Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.

Original languageEnglish
Pages (from-to)3091-3098
Number of pages8
JournalFuture Oncology
Issue number22
Publication statusPublished - Nov 1 2015


  • Gleason score
  • prostate cancer
  • urotensin II receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer'. Together they form a unique fingerprint.

Cite this